Q-omics provides the consensus-scored LYRM7 profile across patient tissues and cancer cell-line models. LYRM7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LYRM7 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LYRM7 RNA expression shows 20,038 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where LYRM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYRM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYRM7 survival associations across molecular data types. LYRM7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYRM7 RNA expression–survival associations across cancer types. High LYRM7 expression shows unfavorable associations in UVM, KICH, SCLC and ESCA, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LYRM7 RNA expression.
This table summarizes LYRM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LYRM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYRM7 shows lower tumor expression in THCA, KIRP, BRCA, UCEC and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher LYRM7 RNA expression in normal versus tumor tissue (log2 FC = −1.482, t-test p < 0.001).
This table shows molecular features associated with LYRM7 in patient tissues and cancer cell lines. In patient samples, LYRM7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LYRM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
